Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.39 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4967686 | 0.98 | HRH1 (0.45) | CYP17A1HRH1HDAC8TBXAS1FAAH | |
| SCHEMBL4967086 | 0.89 | CYP17A1 (0.47) | CYP17A1CYP19A1RAB9AGPR119 | |
| SCHEMBL9196120 | 0.84 | MAPT (0.56) | HDAC8FAAHCES1MAPTRXFP1 | |
| Hydrochloric Acid SCHEMBL1677705 | 0.83 | CYP17A1 (0.41) | CYP17A1TBXAS1RAB9ACYP3A4 | |
| SCHEMBL27586622 | 0.83 | MAPT (0.59) | HDAC8FAAHCES1MAPTRXFP1 | |
| SCHEMBL6643753 | 0.81 | HPGD (0.49) | HRH1TBXAS1FAAHCES1MAPT | |
| SCHEMBL6643632 | 0.81 | HPGD (0.49) | HRH1TBXAS1FAAHCES1MAPT | |
| SCHEMBL6646146 | 0.81 | HPGD (0.49) | HRH1TBXAS1FAAHCES1MAPT | |
| SCHEMBL27643469 | 0.81 | CYP17A1 (0.41) | CYP17A1HRH1CYP19A1RAB9AGPR119 | |
| SCHEMBL7955579 | 0.80 | HDAC8 (0.44) | HDAC8FAAHCES1MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023049790-A2 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| EP-1585791-B1 | HYDROPHILIC, THIOL-REACTIVE CYANINE DYES AND CONJUGATES THEREOF WITH BIOMOLECULES FOR FLUORESCENCE DIAGNOSIS | BAYER SCHERING PHARMA AG (DE) | 2008-09-24 | — | — | EP | disclosed |
| CN-101022835-A | Antibody conjugated cyanine dyes for the diagnosis of micrometastasis | BAYER SCHERING PHARMA AG (DE) | 2007-08-22 | — | — | CN | disclosed |
| EP-1816475-A1 | Use of cyanine dyes for the diagnosis of disease associated with angiogenesis | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1784226-A2 | CYANINE DYES CONJUGATED WITH ANTIBODIES FOR THE DIAGNOSIS OF MICROMETASTASIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-05-16 | — | — | EP | disclosed |
| CN-1742057-A | Hydrophilic, thiol-reactive cyanine dyes and conjugates thereof with biomolecules for fluorescence diagnosis | SCHERING AG (DE) | 2006-03-01 | — | — | CN | disclosed |
| US-20060039863-A1 | Use of cyanine dyes for the diagnosis of disease associated with angiogenesis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-02-23 | — | — | US | disclosed |
| WO-2006008179-A2 | CYANINE DYES CONJUGATED WITH ANTIBODIES FOR THE DIAGNOSIS OF MICROMETASTASIS | SCHERING AG (DE) | 2006-01-26 | — | — | WO | disclosed |
| EP-1619501-A1 | Use of cyanine dyes for the diagnosis of disease associated with angiogenesis | Schering AG (DE) | 2006-01-25 | — | — | EP | disclosed |
| EP-1585791-A1 | HYDROPHILIC, THIOL-REACTIVE CYANINE DYES AND CONJUGATES THEREOF WITH BIOMOLECULES FOR FLUORESCENCE DIAGNOSIS | Schering AG (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20040260072-A1 | Hydrophilic, thiol-reactive cyanine dyes and conjugates thereof with biomolecules for fluorescence diagnosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-23 | — | — | US | disclosed |
| WO-2004065491-A1 | HYDROPHILIC, THIOL-REACTIVE CYANINE DYES AND CONJUGATES THEREOF WITH BIOMOLECULES FOR FLUORESCENCE DIAGNOSIS | SCHERING AG (DE) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260072-A1 | Hydrophilic, thiol-reactive cyanine dyes and conjugates thereof with biomolecules for fluorescence diagnosis | TST, ABCG2, SPR | CYP17A1 3749/4885HRH1 2252/4885HDAC8 4366/4885 |
| US-20060039863-A1 | Use of cyanine dyes for the diagnosis of disease associated with angiogenesis | MYADM, CD14, CD68 | CYP17A1 3034/4885HRH1 3397/4885HDAC8 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.